Condition: Advanced Soft Tissue Sarcomas · Sponsor: Ruijin Hospital
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced soft tissue sarcomas.
This description comes directly from the study's public registry record.
Jiajia Hu · 13524945287 · jiajiahu@shsmu.edu.cn
Always discuss trial participation with your own doctor first.
| Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06644287